{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:52:55Z","timestamp":1781632375248,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to characterize the risk signals and clinical features of pembrolizumab-associated neutropenia reported as serious adverse events (SAEs) in the US FDA Adverse Event Reporting System (FAERS), and the association between concomitant chemotherapy and time-to-onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective pharmacovigilance study, SAE reports from FAERS (2021Q1\u20132024Q2) with pembrolizumab designated as the primary suspect drug were analyzed. Among 14,747 pembrolizumab-associated SAE reports, 856 with the Preferred Term \u201cneutropenia\u201d were identified and characterized. Clinical characteristics were summarized, and subgroup analyses explored associations between concomitant chemotherapy and TTO, as well as between sex and the reporting odds ratio (ROR). A supplementary analysis of febrile neutropenia (FN) cases was conducted to assess clinical severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 14,747 SAEs, 856 were neutropenia cases, for which a strong signal of disproportional reporting was detected (ROR\u2009=\u20095.23, 95% CI: 4.88\u20135.60). Median patient age was 61.0 years, and the reported mortality rate was 19.4%. A higher ROR was observed in females (7.06) than males (4.42), a difference likely influenced by the underlying distribution of cancer types and the 9.8% missing data for sex, rather than indicating an intrinsic sex-related risk. The overall median TTO was 19.0 days, with the concomitant chemotherapy group (N\u2009=\u2009268) showing a shorter median TTO (14.5 days) than the non-chemotherapy group (N\u2009=\u200955, 39.0 days; p\u2009=\u20090.0006). Among 311 FN cases, 86.5% (269\/311) occurred in the concomitant chemotherapy group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pembrolizumab-associated neutropenia represents a notable safety signal in FAERS. The observed early-onset pattern, particularly in the context of concomitant chemotherapy, provides real-world evidence characterizing the clinical features of this adverse event.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15630-1","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T05:45:39Z","timestamp":1769233539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk signals and clinical characteristics of serious adverse events of neutropenia associated with pembrolizumab: a FAERS database study"],"prefix":"10.1186","volume":"26","author":[{"given":"Jianhui","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"15630_CR1","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.21.02885","volume":"41","author":"G de Castro Jr","year":"2023","unstructured":"de Castro G Jr, Hui R, Radeski D, et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non\u2013small-cell lung cancer and programmed death ligand-1 tumor proportion score\u2009\u2265\u20091% in the KEYNOTE-042 study. J Clin Oncol. 2023;41:1986\u201391. https:\/\/doi.org\/10.1200\/JCO.21.02885.","journal-title":"J Clin Oncol"},{"key":"15630_CR2","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","volume":"12","author":"G Kwok","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016;12:2777\u201389. https:\/\/doi.org\/10.1080\/21645515.2016.1199310.","journal-title":"Hum Vaccin Immunother"},{"key":"15630_CR3","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.2147\/CMAR.S151023","volume":"11","author":"P du Rusquec","year":"2019","unstructured":"du Rusquec P, de Calbiac O, Robert M, Campone M, Frenel JS. Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. Cancer Manag Res. 2019;11:4297\u2013312. https:\/\/doi.org\/10.2147\/CMAR.S151023.","journal-title":"Cancer Manag Res"},{"key":"15630_CR4","doi-asserted-by":"publisher","first-page":"111606","DOI":"10.1016\/j.intimp.2024.111606","volume":"129","author":"DC Moore","year":"2024","unstructured":"Moore DC, Elmes JB, Arnall JR, Strassel SA, Patel JN. PD-1\/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review. Int Immunopharmacol. 2024;129:111606. https:\/\/doi.org\/10.1016\/j.intimp.2024.111606.","journal-title":"Int Immunopharmacol"},{"key":"15630_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10238-025-01688-x","volume":"25","author":"X Han","year":"2025","unstructured":"Han X, Xu J, Cui M, et al. Haematological toxicities with immune checkpoint inhibitors in digestive system tumors: a systematic review and network meta-analysis of randomized controlled trials. Clin Exp Med. 2025;25:157. https:\/\/doi.org\/10.1007\/s10238-025-01688-x.","journal-title":"Clin Exp Med"},{"key":"15630_CR6","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1182\/blood.2020009016","volume":"139","author":"MH Kroll","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C. Hematologic complications of immune checkpoint inhibitors. Blood. 2022;139:3594\u2013604. https:\/\/doi.org\/10.1182\/blood.2020009016.","journal-title":"Blood"},{"key":"15630_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10555-025-10260-8","volume":"44","author":"JJ Adashek","year":"2025","unstructured":"Adashek JJ, Moran JA, Le DT, et al. Lessons learned from a decade of immune checkpoint inhibition: the good, the bad, and the ugly. Cancer Metastasis Rev. 2025;44:43. https:\/\/doi.org\/10.1007\/s10555-025-10260-8.","journal-title":"Cancer Metastasis Rev"},{"key":"15630_CR8","doi-asserted-by":"publisher","first-page":"1407709","DOI":"10.3389\/fphar.2024.1407709","volume":"15","author":"X Zhang","year":"2024","unstructured":"Zhang X, Ren X, Zhu T, Zheng W, Shen C, Lu C. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for Sunitinib. Front Pharmacol. 2024;15:1407709. https:\/\/doi.org\/10.3389\/fphar.2024.1407709.","journal-title":"Front Pharmacol"},{"key":"15630_CR9","doi-asserted-by":"publisher","first-page":"1391356","DOI":"10.3389\/fphar.2024.1391356","volume":"15","author":"MT Wen","year":"2024","unstructured":"Wen MT, Li JC, Lu BW, et al. Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS). Front Pharmacol. 2024;15:1391356. https:\/\/doi.org\/10.3389\/fphar.2024.1391356.","journal-title":"Front Pharmacol"},{"key":"15630_CR10","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048.","journal-title":"Int J Med Sci"},{"key":"15630_CR11","unstructured":"U.S. Food and Drug Administration. (2024) Postmarketing safety reports. Code of Federal Regulations, Title 21, Section 314.80. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-D\/part-314\/subpart-B\/section-314.80. Accessed 31 Aug 2025."},{"key":"15630_CR12","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2025) Introductory Guide MedDRA Version 28.0. https:\/\/www.meddra.org\/how-to-use\/support-documentation. Accessed 31 Aug 2025."},{"key":"15630_CR13","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","volume":"3","author":"PM Cutroneo","year":"2024","unstructured":"Cutroneo PM, Sartori D, Tuccori M, et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front Drug Saf Regul. 2024;3:1323057. https:\/\/doi.org\/10.3389\/fdsfr.2023.1323057.","journal-title":"Front Drug Saf Regul"},{"key":"15630_CR14","unstructured":"European Medicines Agency. (2017) Guideline on good pharmacovigilance practices (GVP) Module IX \u2013 Signal management (Rev 1). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf. Accessed 28 Aug 2025."},{"key":"15630_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"15630_CR16","unstructured":"National Cancer Institute. (2025) Age and Cancer Risk. https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/risk\/age. Accessed 31 Aug 2025."},{"key":"15630_CR17","doi-asserted-by":"publisher","first-page":"e4614","DOI":"10.1097\/MD.0000000000004614","volume":"95","author":"ML Plasilova","year":"2016","unstructured":"Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR. Features of triple-negative breast cancer: analysis of 38,813 cases from the National cancer database. Med (Baltim). 2016;95:e4614. https:\/\/doi.org\/10.1097\/MD.0000000000004614.","journal-title":"Med (Baltim)"},{"key":"15630_CR18","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.21.02377","volume":"40","author":"JM Unger","year":"2022","unstructured":"Unger JM, Vaidya R, Albain KS, et al. Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials. J Clin Oncol. 2022;40:1474\u201386. https:\/\/doi.org\/10.1200\/JCO.21.02377.","journal-title":"J Clin Oncol"},{"key":"15630_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s40425-019-0648-3","volume":"7","author":"AR Naqash","year":"2019","unstructured":"Naqash AR, Appah E, Yang LV, et al. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint Inhibition. J Immunother Cancer. 2019;7:169. https:\/\/doi.org\/10.1186\/s40425-019-0648-3.","journal-title":"J Immunother Cancer"},{"key":"15630_CR20","doi-asserted-by":"publisher","first-page":"e45738","DOI":"10.7759\/cureus.45738","volume":"15","author":"Y Peng","year":"2023","unstructured":"Peng Y, Du W, Zhou T, Liu X, He X, Lei Y. Isolated neutropenia due to immune checkpoint inhibitors. Cureus. 2023;15:e45738. https:\/\/doi.org\/10.7759\/cureus.45738.","journal-title":"Cureus"},{"key":"15630_CR21","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","volume":"6","author":"N Delanoy","year":"2019","unstructured":"Delanoy N, Michot JM, Comont T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 2019;6:e48\u201357. https:\/\/doi.org\/10.1016\/S2352-3026(18)30175-3.","journal-title":"Lancet Haematol"},{"key":"15630_CR22","doi-asserted-by":"publisher","first-page":"765608","DOI":"10.3389\/fonc.2021.765608","volume":"11","author":"A Zaremba","year":"2021","unstructured":"Zaremba A, Kramer R, De Temple V, et al. Grade 4 neutropenia secondary to immune checkpoint inhibition\u2014a descriptive observational retrospective multicenter analysis. Front Oncol. 2021;11:765608. https:\/\/doi.org\/10.3389\/fonc.2021.765608.","journal-title":"Front Oncol"},{"key":"15630_CR23","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","volume":"32","author":"D Rodr\u00edguez-Abreu","year":"2021","unstructured":"Rodr\u00edguez-Abreu D, Powell SF, Hochmair MJ, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32:881\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.04.008.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15630-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15630-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15630-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:03:45Z","timestamp":1781629425000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15630-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15630"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15630-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a retrospective analysis of a publicly available and anonymized database (FAERS). Therefore, institutional review board approval and ethical approval were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This study does not contain any individual person\u2019s data in any form that would require consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"265"}}